The TRAUMAKINE consortium has received a grant from the 7th Framework Programme for Research and Technological Development of the Cooperation Work Programme: Health-2012.
The Call for Proposal was HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2012-INNOVATION-1.
This call was designed to support preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trials) of EU designated orphan medicinal products. The involvement of industry, in particular SMEs, was strongly recommended and the orphan medicinal product needed to be granted the EU orphan designation at the latest on the date of the call closure.
It was expected that: